Oxford Expression Technologies
Private Company
Funding information not available
Overview
Oxford Expression Technologies (OET) is a private biotechnology company founded in 2001 (incorporated 2007) as a spin-out from Oxford Brookes University and the Natural Environment Research Council. The company has established itself as a leading global provider of baculovirus expression products and services, centered on its proprietary flash BAC™ platform for high-throughput recombinant protein and virus-like particle production. OET leverages its expertise in insect, mammalian, and bacterial expression systems to serve clients in drug discovery, vaccine development, and diagnostics, while also pursuing its own internal vaccine development programs through grant-funded collaborations.
Technology Platform
Proprietary flash BAC™ baculovirus expression system for high-throughput recombinant protein and virus-like particle (VLP) production. Also expanding into BacMam (mammalian cell) and bacterial expression systems.
Opportunities
Risk Factors
Competitive Landscape
OET competes in the protein expression market against large reagent suppliers (e.g., Thermo Fisher, Merck) offering alternative expression systems (mammalian, yeast, E. coli), and against other specialist baculovirus service providers and CROs. Its differentiation lies in its proprietary flash BAC™ technology, deep expertise in insect cell systems, and its hybrid product/service model.